Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02967133 · ClinicalTrials.gov registry record · Phase 2
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Alliance Foundation Trials.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02967133: Clinical Trial Phase 2 study, sponsored by Alliance Foundation Trials.
NCT02967133 is a Phase 2 study that was terminated before completion, run by Alliance Foundation Trials. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02967133, a Phase 2 study, was terminated before completion, sponsored by Alliance Foundation Trials.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The optimal prioritization of second-line chemotherapy and immune therapy based on demographic or biomarker data is an area of ongoing investigation. The hypothesis of this study is that there may be an additive or synergistic antitumor effect of combined chemotherapy and nivolumab in the second-line treatment of NSCLC as an important concept to test in a clinical trial. Previously treated NSCLC remains a setting of unmet clinical need despite recent clinical research progress. Early progression for a subset of NSCLC patients receiving nivolumab is a specific area of clinical need.
Primary Outcome
This study will compare the progression-free survival of patients with advanced stage non-small cell lung cancer whose cancer has progressed after standard first-line platinum based doublet chemotherapy is improved with nivolumab plus nab-paclitaxel compared to nivolumab alone. A progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In additi
Interventions
- DRUG Nivolumab
- DRUG nab-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-01 |
| Phase | Phase 2 |
Why NCT02967133 stopped before completion
NCT02967133 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02967133 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02967133 about?
NCT02967133 is a clinical study titled "A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer". The optimal prioritization of second-line chemotherapy and immune therapy based on demographic or biomarker data is an area of ongoing investigation. The hypothesis of this study is that there may be an additive or synergistic antitumor effect of combined chemotherapy and nivolumab in the second-lin...
What is the current status of trial NCT02967133?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2016-12. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02967133?
The interventions under investigation include: Nivolumab (DRUG), nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02967133?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02967133's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia